Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Blood cancers, Thrombocythaemia
Closed
Phase 3
This trial is looking at treatment to control symptoms of primary thrombocythaemia (PT).
Primary thrombocythaemia is a condition which causes too many platelets to be made in the bone marrow. It increases the risk of developing blood clots or having a stroke. There is a small chance that primary thrombocythaemia may develop into a cancer of the white blood cells (leukaemia).
Doctors can treat PT with drugs such as aspirin and a drug called hydroxycarbamide (used to be called hydroxyurea).
The aim of this trial is to follow people who have been diagnosed with PT and collect information about the condition and the side effects of treatment.
Recruitment start: 1 June 1997
Recruitment end: 30 April 2013
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Tony Green
Dr Claire Harrison
Cambridge University Hospitals NHS Foundation Trust
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
University of Cambridge
Last reviewed: 21 Jul 2016
CRUK internal database number: 57